N
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Nisreen Akel's research focuses on bone metabolism and its disruption in conditions such as diabetes and glucocorticoid-induced bone loss. Her work investigates therapeutic strategies to reverse or prevent skeletal deterioration. Akel has studied the role of chaperone-mediated autophagy in bone mass regulation and explored the efficacy of bone-targeted inhibitors and antibodies in preclinical models. Her publications include studies on reversing diabetic bone signatures in mice using anabolic therapies and correcting periodontal disease in type 2 diabetic mice with sclerostin antibodies. Akel also explores advanced genetic engineering techniques, comparing CRISPR interference with the Cre-loxP system for cell type specificity. She has collaborated with researchers at the University of Arkansas for Medical Sciences, including Teresita Bellido, Amy Y. Sato, Gaston Troncoso, and Betiana Perez, on multiple shared publications. Akel's scholarship metrics include an h-index of 19, with 41 total publications and over 2,000 citations.
Metrics
- h-index: 19
- Publications: 42
- Citations: 2,039
Selected Publications
-
Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective <i>via</i> Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss (2024)
-
Sclerostin antibody corrects periodontal disease in type 2 diabetic mice (2024)
-
Loss of chaperone‐mediated autophagy does not alter age‐related bone loss in male mice (2024)
-
THU346 Repairing Skeletal Deterioration In Diabetes With Bone Anabolic Therapies (2023)
-
CRISPR interference provides increased cell type-specificity compared to the Cre-loxP system (2023)
-
Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice (2023)
-
Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice (2023)
-
Reversal of the diabetic bone signature with anabolic therapies in mice (2023)
-
Loss of chaperone-mediated autophagy is associated with low vertebral cancellous bone mass (2022)
Collaboration Network
Top Collaborators
Teresita Bellido
Winthrop Rockefeller Foundation
6 shared publications
In database
- Reversal of the diabetic bone signature with anabolic therapies in mice
- Sclerostin antibody corrects periodontal disease in type 2 diabetic mice
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
- Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective <i>via</i> Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
Showing 5 of 6 shared publications
Silvia Marino
University of Arkansas for Medical Sciences (US)
5 shared publications
- Reversal of the diabetic bone signature with anabolic therapies in mice
- Sclerostin antibody corrects periodontal disease in type 2 diabetic mice
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
- THU346 Repairing Skeletal Deterioration In Diabetes With Bone Anabolic Therapies
Amy Y. Sato
University of Arkansas for Medical Sciences
5 shared publications
In database
- Reversal of the diabetic bone signature with anabolic therapies in mice
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
- Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective <i>via</i> Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
- THU346 Repairing Skeletal Deterioration In Diabetes With Bone Anabolic Therapies
Intawat Nookaew
University of Arkansas for Medical Sciences
5 shared publications
In database
- Reversal of the diabetic bone signature with anabolic therapies in mice
- CRISPR interference provides increased cell type-specificity compared to the Cre-loxP system
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
- THU346 Repairing Skeletal Deterioration In Diabetes With Bone Anabolic Therapies
Shenyang Li
University of Arkansas for Medical Sciences (US)
4 shared publications
- Reversal of the diabetic bone signature with anabolic therapies in mice
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
- THU346 Repairing Skeletal Deterioration In Diabetes With Bone Anabolic Therapies
Meloney Cregor
University of Arkansas for Medical Sciences (US)
4 shared publications
- Reversal of the diabetic bone signature with anabolic therapies in mice
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
- THU346 Repairing Skeletal Deterioration In Diabetes With Bone Anabolic Therapies
Betiana Perez
University of Arkansas for Medical Sciences
4 shared publications
In database
- Reversal of the diabetic bone signature with anabolic therapies in mice
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
- THU346 Repairing Skeletal Deterioration In Diabetes With Bone Anabolic Therapies
Gaston Troncoso
University of Arkansas for Medical Sciences
4 shared publications
In database
- Reversal of the diabetic bone signature with anabolic therapies in mice
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
- THU346 Repairing Skeletal Deterioration In Diabetes With Bone Anabolic Therapies
Jomeeka Meeks
University of Arkansas for Medical Sciences
4 shared publications
In database
- Reversal of the diabetic bone signature with anabolic therapies in mice
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
- THU346 Repairing Skeletal Deterioration In Diabetes With Bone Anabolic Therapies
Stuart B. Berryhill
University of Arkansas for Medical Sciences
3 shared publications
In database
- Loss of chaperone-mediated autophagy is associated with low vertebral cancellous bone mass
- CRISPR interference provides increased cell type-specificity compared to the Cre-loxP system
- Loss of chaperone‐mediated autophagy does not alter age‐related bone loss in male mice
Dominique J. Laster
University of Arkansas for Medical Sciences
3 shared publications
In database
- Loss of chaperone-mediated autophagy is associated with low vertebral cancellous bone mass
- CRISPR interference provides increased cell type-specificity compared to the Cre-loxP system
- Loss of chaperone‐mediated autophagy does not alter age‐related bone loss in male mice
Julie Crawford
University of Arkansas for Medical Sciences
3 shared publications
In database
- Loss of chaperone-mediated autophagy is associated with low vertebral cancellous bone mass
- CRISPR interference provides increased cell type-specificity compared to the Cre-loxP system
- Loss of chaperone‐mediated autophagy does not alter age‐related bone loss in male mice
Melda Onal
University of Arkansas for Medical Sciences
3 shared publications
In database
- Loss of chaperone-mediated autophagy is associated with low vertebral cancellous bone mass
- CRISPR interference provides increased cell type-specificity compared to the Cre-loxP system
- Loss of chaperone‐mediated autophagy does not alter age‐related bone loss in male mice
Meghan Jones
University of Arkansas for Medical Sciences (US)
3 shared publications
- Reversal of the diabetic bone signature with anabolic therapies in mice
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
Scott Stewart
University of Arkansas for Medical Sciences (US)
2 shared publications
- Reversal of the diabetic bone signature with anabolic therapies in mice
- Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice
Similar Researchers
Based on overlapping research topics
Scott Stewart
University of Arkansas for Medical Sciences
Bone Metabolism and Diseases
Metabolism and Genetic Disorders
Diabetes Management and Research
Gaston Troncoso
University of Arkansas for Medical Sciences
Bone Metabolism and Diseases
Metabolism and Genetic Disorders
Diabetes Management and Research
Betiana Perez
University of Arkansas for Medical Sciences
Bone Metabolism and Diseases
Metabolism and Genetic Disorders
Diabetes Management and Research
Scott A. Stuart
University of Arkansas for Medical Sciences
Bone Metabolism and Diseases
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies
Andrea Giovanna Aguirre-Pérez
Arkansas State University
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies
Diabetes Management and Research
Amy Y. Sato
University of Arkansas for Medical Sciences
Bone Metabolism and Diseases
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies